ATE314480T1 - Fusionsproteine aus hirudin und proinsulin oder insulin - Google Patents

Fusionsproteine aus hirudin und proinsulin oder insulin

Info

Publication number: ATE314480T1
Authority: AT; Austria
Prior art keywords: proinsulin; hirudin; insulin; fusion proteins; protein
Prior art date: 2001-02-20

Application number

AT02711847T

Other languages

English (en)

Inventor

Paul Habermann

Johann Ertl

Original Assignee

Sanofi Aventis Deutschland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-20

Filing date

2002-02-08

Publication date

2006-01-15

2002-02-08 Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland

2006-01-15 Application granted granted Critical

2006-01-15 Publication of ATE314480T1 publication Critical patent/ATE314480T1/de

Links

102000037865 fusion proteins Human genes 0.000 title abstract 3
108020001507 fusion proteins Proteins 0.000 title abstract 3
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
102000007625 Hirudins Human genes 0.000 title 1
108010007267 Hirudins Proteins 0.000 title 1
102000004877 Insulin Human genes 0.000 title 1
108090001061 Insulin Proteins 0.000 title 1
108010076181 Proinsulin Proteins 0.000 title 1
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 title 1
229940006607 hirudin Drugs 0.000 title 1
229940125396 insulin Drugs 0.000 title 1
102000004169 proteins and genes Human genes 0.000 abstract 3
108090000623 proteins and genes Proteins 0.000 abstract 3
230000001580 bacterial effect Effects 0.000 abstract 1
230000004927 fusion Effects 0.000 abstract 1
239000006228 supernatant Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Diabetes (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Medicinal Chemistry (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Tropical Medicine & Parasitology (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Toxicology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT02711847T 2001-02-20 2002-02-08 Fusionsproteine aus hirudin und proinsulin oder insulin ATE314480T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10108212A DE10108212A1 (de)	2001-02-20	2001-02-20	Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
PCT/EP2002/001307 WO2002068660A1 (en)	2001-02-20	2002-02-08	Fusion protein for the secretion of a protein of interest into the supernatant of the bacterial culture

Publications (1)

Publication Number	Publication Date
ATE314480T1 true ATE314480T1 (de)	2006-01-15

Family

ID=7674913

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02711847T ATE314480T1 (de)	2001-02-20	2002-02-08	Fusionsproteine aus hirudin und proinsulin oder insulin

Country Status (18)

Country	Link
EP (1)	EP1364029B1 (de)
JP (1)	JP4243104B2 (de)
KR (1)	KR100858009B1 (de)
CN (1)	CN100500853C (de)
AT (1)	ATE314480T1 (de)
AU (1)	AU2002231784B2 (de)
BR (1)	BRPI0207394B8 (de)
CA (1)	CA2438886C (de)
DE (2)	DE10108212A1 (de)
DK (1)	DK1364029T3 (de)
ES (1)	ES2254658T3 (de)
IL (1)	IL157414A0 (de)
MX (1)	MXPA03007114A (de)
NO (1)	NO331271B1 (de)
NZ (1)	NZ527643A (de)
PE (1)	PE20020876A1 (de)
WO (1)	WO2002068660A1 (de)
ZA (1)	ZA200305869B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9453251B2 (en)	2002-10-08	2016-09-27	Pfenex Inc.	Expression of mammalian proteins in Pseudomonas fluorescens
CN1882605B (zh)	2003-11-21	2012-07-11	陶氏环球技术公司	使用Sec-系统分泌的改进的表达系统
EP2434016B1 (de)	2004-01-16	2018-11-07	Pfenex Inc.	Expression von säugerproteinen in pseudomonas fluorescens
EP1774017B1 (de)	2004-07-26	2013-05-15	Pfenex Inc.	Verfahren zur verbesserten proteinexpression durch strain-engineering
DE102006031955A1 (de)	2006-07-11	2008-01-17	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
DE102006031962A1 (de)	2006-07-11	2008-01-17	Sanofi-Aventis Deutschland Gmbh	Amidiertes Insulin Glargin
DE102006050332A1 (de)	2006-10-25	2008-04-30	Wacker Chemie Ag	DNS-Konstrukt und Verfahren zur fermentativen Herstellung von Fusionsproteinen
CA2677179C (en)	2007-01-31	2016-02-16	Dow Global Technologies Inc.	Bacterial leader sequences for increased expression
US9394571B2 (en)	2007-04-27	2016-07-19	Pfenex Inc.	Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en)	2007-04-27	2017-02-28	Pfenex, Inc.	Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
DE102008025008A1 (de)	2008-05-24	2009-11-26	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003566A1 (de)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
BRPI0907119A2 (pt)	2008-01-09	2015-07-14	Sanofi Aventis Deutschland	Derivados de insulina tendo um perfil de ação de tempo extremamente retardado
DE102008003568A1 (de)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
AU2009203809B2 (en)	2008-01-09	2013-07-25	Sanofi-Aventis Deutschland Gmbh	Novel insulin derivatives having an extremely delayed time-action profile
DE102008025007A1 (de)	2008-05-24	2009-11-26	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
EP2344524B1 (de) *	2008-10-02	2019-12-04	Unitargeting Research As	Kit zur optimierung der proteinsynthese/sezernierung
PT3228320T (pt)	2008-10-17	2020-03-26	Sanofi Aventis Deutschland	Combinação de uma insulina e de um agonista do glp-1
KR101853606B1 (ko)	2009-07-06	2018-05-03	사노피-아벤티스 도이칠란트 게엠베하	메티오닌을 함유하는 수성 인슐린 제제
DK2498802T3 (en)	2009-11-13	2015-04-13	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
KR101337322B1 (ko)	2009-11-13	2013-12-06	사노피-아벤티스 도이칠란트 게엠베하	Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
ES2606554T3 (es)	2010-08-30	2017-03-24	Sanofi-Aventis Deutschland Gmbh	Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PL2750699T3 (pl)	2011-08-29	2015-12-31	Sanofi Aventis Deutschland	Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
AR087744A1 (es)	2011-09-01	2014-04-16	Sanofi Aventis Deutschland	Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
HK1222331A1 (zh)	2013-03-12	2017-06-30	通用医疗公司	修饰的缪勒抑制物质(mis)蛋白及其用於疾病治疗的用途
US11135269B2 (en)	2013-12-11	2021-10-05	The General Hospital Corporation	Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
AU2015359376B2 (en)	2014-12-12	2021-09-09	Sanofi-Aventis Deutschland Gmbh	Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1985004418A1 (fr) *	1984-03-27	1985-10-10	Transgene S.A.	Vecteurs d'expression de l'hirudine, cellules transformees et procede de preparation de l'hirudine
GB8927722D0 (en) *	1989-12-07	1990-02-07	British Bio Technology	Proteins and nucleic acids
ES2129749T3 (es) *	1990-11-08	1999-06-16	Japan Energy Corp	Vector de secrecion, microorganismos transformados que contienen el indicado vector y produccion de un producto a partir de dicho microorganismo.
CA2128689A1 (en) *	1992-09-28	1995-04-06	Harold T. Pehr	Kicker latch for container closures
DE10033195A1 (de) *	2000-07-07	2002-03-21	Aventis Pharma Gmbh	Bifunktionale Fusionsproteine aus Hirudin und TAP

2001
- 2001-02-20 DE DE10108212A patent/DE10108212A1/de not_active Withdrawn
2002
- 2002-02-06 PE PE2002000081A patent/PE20020876A1/es not_active Application Discontinuation
- 2002-02-08 WO PCT/EP2002/001307 patent/WO2002068660A1/en not_active Ceased
- 2002-02-08 AT AT02711847T patent/ATE314480T1/de active
- 2002-02-08 DK DK02711847T patent/DK1364029T3/da active
- 2002-02-08 DE DE60208343T patent/DE60208343T2/de not_active Expired - Lifetime
- 2002-02-08 JP JP2002568754A patent/JP4243104B2/ja not_active Expired - Lifetime
- 2002-02-08 MX MXPA03007114A patent/MXPA03007114A/es active IP Right Grant
- 2002-02-08 KR KR1020037010943A patent/KR100858009B1/ko not_active Expired - Lifetime
- 2002-02-08 CA CA2438886A patent/CA2438886C/en not_active Expired - Lifetime
- 2002-02-08 CN CNB028068505A patent/CN100500853C/zh not_active Expired - Lifetime
- 2002-02-08 BR BRPI0207394A patent/BRPI0207394B8/pt not_active IP Right Cessation
- 2002-02-08 AU AU2002231784A patent/AU2002231784B2/en not_active Expired
- 2002-02-08 ES ES02711847T patent/ES2254658T3/es not_active Expired - Lifetime
- 2002-02-08 EP EP02711847A patent/EP1364029B1/de not_active Expired - Lifetime
- 2002-02-08 NZ NZ527643A patent/NZ527643A/en not_active IP Right Cessation
- 2002-02-08 IL IL15741402A patent/IL157414A0/xx active IP Right Grant
2003
- 2003-07-30 ZA ZA200305869A patent/ZA200305869B/en unknown
- 2003-08-19 NO NO20033673A patent/NO331271B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
NZ527643A (en)	2005-07-29
CN100500853C (zh)	2009-06-17
AU2002231784B2 (en)	2006-10-26
DK1364029T3 (da)	2006-05-08
BRPI0207394B1 (pt)	2015-06-16
EP1364029A1 (de)	2003-11-26
MXPA03007114A (es)	2003-11-18
NO331271B1 (no)	2011-11-14
ES2254658T3 (es)	2006-06-16
PE20020876A1 (es)	2002-11-05
BRPI0207394B8 (pt)	2021-05-25
IL157414A0 (en)	2004-03-28
JP4243104B2 (ja)	2009-03-25
DE60208343D1 (de)	2006-02-02
NO20033673L (no)	2003-10-17
BR0207394A (pt)	2004-02-10
ZA200305869B (en)	2004-06-25
JP2004518444A (ja)	2004-06-24
NO20033673D0 (no)	2003-08-19
CN1529757A (zh)	2004-09-15
EP1364029B1 (de)	2005-12-28
HK1065335A1 (zh)	2005-02-18
KR20030074842A (ko)	2003-09-19
CA2438886C (en)	2013-07-23
DE10108212A1 (de)	2002-08-22
WO2002068660A1 (en)	2002-09-06
KR100858009B1 (ko)	2008-09-11
CA2438886A1 (en)	2002-09-06
DE60208343T2 (de)	2006-06-22

Legal Events

Date

Code

Title

Description

2007-01-15

UEP

Publication of translation of european patent specification

Ref document number: 1364029

Country of ref document: EP

2007-07-15

EEIH

Change in the person of patent owner

Publication	Publication Date	Title
DE60208343D1 (de)	2006-02-02	FUSIONSPROTEINE aus hirudin und proinsulin oder insulin
LTC1641823I2 (lt)	2016-12-12	GLP-1 analogo sulieti baltymai
WO2005021592A3 (en)	2005-06-09	Enhancing the circulating half-life of interleukin-2 proteins
PL1699822T3 (pl)	2008-08-29	Białka fuzyjne IL-7 z częściami przeciwciała, ich otrzymywanie oraz ich zastosowanie
EP1534834A4 (de)	2006-05-24	Denaturierungsmittel-stabile und/oder proteaseresistente chaperon-ähnliche oligomere proteine, diese codierende polynukleotide, ihre verwendungen sowie verfahren zur erhohung einer spezifischen aktivitat davon
DE69435307D1 (de)	2010-09-16	Bazillus Thuringiensis und dessen insektizide Proteine
AU2002214542A1 (en)	2002-04-08	Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
WO2006097708A3 (en)	2007-01-25	Affinity purification of protein
EP1383907A4 (de)	2005-06-15	Isolierte menschliche protease-proteine, menschliche protease-proteine codierende nukleinsäuremoleküle sowie verwendungen davon
AU2001288363A1 (en)	2002-03-04	Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
AU2002256019A1 (en)	2002-10-15	Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
AU2003287108A1 (en)	2004-06-23	Fusion of the e2 protein of csfv with kdel , vts and/or ubiquitin for expression in transgenic plants for vaccine production
AU2002229060A1 (en)	2002-07-01	Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
EP1395674A4 (de)	2005-04-20	Isolierte menschliche proteaseproteine, menschliche proteaseproteine codierende nukleinsäuremoleküle und verwendungen davon
AU2002232452A1 (en)	2002-06-18	Human transporter proteins, nucleic acid molecules encoding them,and uses thereof
AU2002257075A1 (en)	2002-10-08	Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
AU2001253804A1 (en)	2001-11-07	Isolated human transporter proteins, nucleic acid molecules encoding the same, and uses thereof
WO2003016465A3 (en)	2003-10-23	Cell cycle regulator protein
AU2003217864A1 (en)	2003-09-16	Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
EP1419251A4 (de)	2005-05-04	Isolierte menschliche transporterproteine, menschliche transporterproteine codierende nukleinsäuremoleküle sowie verwendungen davon
AU2003215179A1 (en)	2003-09-09	Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and used thereof
EP1384077A4 (de)	2005-06-15	Isolierte menschliche transporterproteine, menschliche transporterproteine codierende nukleinsäuremoleküle sowie verwendungen davon
AU2002307004A1 (en)	2002-10-15	Isolated human phosphatase proteins, nucleic acid molecules encoding human phosphatase proteins, and uses thereof
AU2003209105A1 (en)	2003-09-02	Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
AU2002311750A1 (en)	2002-10-28	Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof